Moderna: FDA Extends RSV Vaccine Review, But No Issues Flagged
By Colin Kellaher
Moderna on Friday said the Food and Drug Administration won't meet its May 12 target action date for a decision on the company's proposed vaccine for respiratory syncytial virus, or RSV, but that the agency hasn't flagged any issues that would prevent an approval.
The company said the FDA cited administrative constraints for the delay, and that the agency is working to complete its review of mRNA-1345 by the end of the month.
Moderna said the FDA hasn't informed the Cambridge, Mass., vaccine maker of any issues related to vaccine safety, efficacy or quality that would prevent the approval of mRNA-1345 for RSV, a contagious virus that is the leading cause of respiratory illness in young children and also poses increased risk to older adults for severe outcomes.
Moderna has previously said it estimates the peak annual RSV market to be about $10 billion, and that it expects a strong RSV vaccine launch this year.
The company also said it remains on track for mRNA-1345 to be reviewed at the Centers for Disease Control and Prevention's advisory committee on immunization practices in late June, which is necessary prior to commercial launch.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 10, 2024 07:48 ET (11:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
4 Wide-Moat Stocks to Buy for the Long Term While They’re Undervalued Today
-
Markets Brief: Four Stocks Made Up 80% of the Gains. Can It Last?
-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
2 Undervalued Dividend Stocks the Best Managers Are Buying
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss